Prichard Heather Ledbetter 4
4 · Humacyte, Inc. · Filed Jun 3, 2024
Insider Transaction Report
Form 4
Humacyte, Inc.HUMA
Prichard Heather Ledbetter
Chief Operating Officer
Transactions
- Exercise/Conversion
Common Stock
2024-05-30$3.07/sh+48,166$147,870→ 50,791 total - Sale
Common Stock
2024-05-30$8.32/sh−48,166$400,741→ 2,625 total - Sale
Common Stock
2024-05-30$8.36/sh−78,779$658,592→ 2,625 total - Exercise/Conversion
Common Stock
2024-05-30$2.56/sh+78,779$201,674→ 81,404 total - Sale
Common Stock
2024-05-30$7.71/sh−61,941$477,565→ 2,625 total - Sale
Common Stock
2024-05-31$9.41/sh−2,625$24,707→ 0 total - Exercise/Conversion
Stock Options (right to buy)
2024-05-30−78,779→ 0 totalExercise: $2.56From: 2018-12-11Exp: 2025-12-11→ Common Stock (78,779 underlying) - Exercise/Conversion
Stock Options (right to buy)
2024-05-30−48,166→ 87,834 totalExercise: $3.07From: 2024-05-08Exp: 2032-12-08→ Common Stock (48,166 underlying)
Footnotes (2)
- [F1]The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $8.36 to $8.44. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $8.31 to $8.42. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.